Cytodyn Inc (CYDY)

[bluefish1]

The chart the BS article used is from a presentation from 2019. BS has no idea what they're talking about.

If you read the presentation that actually goes with the little chart, it states that viral load suppression was shown in 70% of patients, post 10 weeks AFTER taking Leronlimb. That means 70 PERCENT of patients that took the 325mg dose were not showing a viral load AFTER the drug was stopped. This was in addition to patients showing no viral load while on the trial drug.

Not a trial endpoint, and doesn't indicate success or failure of the drug, AT ALL.

More importantly the average length of time that viral load was suppressed, AFTER the drug was stopped, was 38 weeks. The trial was already over at that point.

It would suit a lot of people's narratives if Leronlimab was a failure. That BS (Buyer's Strike) article, is just that.

These numbers are stellar. Thus the reason to submit to the UK and other regulatory agencies.

Thanks for providing more proof of the futility of trying to disprove the science behind Leronlimab.

Here's the REAL link to the presentation the chart was lifted from: https://content.equisolve.net/cytodyn/media/9bb625fefc4872db42ac65d15afea2ae.pdf (Page 7)

DEBUNKED